imCare Biotech
Doylestown, US · Pennsylvania corporation
ImCare Biotech develops diagnostic biomarkers and therapeutic drugs targeting liver diseases, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The company conducts research and development in molecular biology and tissue cultures.
Founders & leadership
XL
Xuanyong LuPresident & Co-Founder
AY
Aaron Yefei LuChief Executive Officer
KK
Karteek KadimisettyChief Science Officer
XL
Xuanyong Lu, PhDNamed on SEC filing
Board
FY
Felix Y. LuBoard director
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 5 rounds · 2020–2023
▶$153.4KraisedJul 2023 · 1 investors · BiotechnologyRule 506(b)
▶$153.4KraisedJul 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Frank FischerDirector
- Matthew LeeDirector
- Aaron LuExecutive Officer, Director
- Xuanyong Lu, PhDExecutive Officer, Director
- Felix Y. LuExecutive Officer, Director
- Offering amount
- $153.4K
- Amount sold
- $153.4K
- First sale
- Jul 2023
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$368.4KraisedApr 2022 · 1 investors · BiotechnologyRule 506(b)
▶$368.4KraisedApr 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xuanyong Lu, PhDDirector
- Felix Y. LuDirector
- Aaron LuExecutive Officer, Director
- Offering amount
- $368.4K
- Amount sold
- $368.4K
- First sale
- Apr 2022
- Incorporated
- Limited Liability Company, Pennsylvania
- Federal exemptions
- 06b
▶$1.3MraisedJul 2021 · 1 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJul 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron LuExecutive Officer, Director
- Felix Y. LuDirector
- Xuanyong Lu, PhDExecutive Officer, Director
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- Proceeds to insiders
- $200K
- First sale
- Jul 2021
- Incorporated
- Limited Liability Company, Pennsylvania
- Federal exemptions
- 06b
▶$1.8MraisedMay 2021 · 4 investors · BiotechnologyRule 506(b)
▶$1.8MraisedMay 2021 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felix Y. LuDirector
- Aaron LuExecutive Officer, Director
- Xuanyong Lu, PhDExecutive Officer, Director
- Offering amount
- $1.8M
- Amount sold
- $1.8M
- Proceeds to insiders
- $450K
- First sale
- Apr 2021
- Incorporated
- Limited Liability Company, Pennsylvania
- Federal exemptions
- 06b
▶$680.1KraisedMar 2020 · 3 investors · BiotechnologyRule 506(b)
▶$680.1KraisedMar 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aaron Yefei LuExecutive Officer, Director
- Felix Y. LuDirector
- Lizhu TangDirector
- Xuanyong LuExecutive Officer, Director
- Offering amount
- $680.1K
- Amount sold
- $680.1K
- Proceeds to insiders
- $50K
- First sale
- Mar 2020
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlapImmatics9 shared keywordsMIG portfolio company taken public.
Imvax8 shared keywordsImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Imcheck6 shared keywordsImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation. Its programs address cancer, infectious disease, and autoimmune disease.
Incyte Corporation5 shared keywordsIncyte is a biopharmaceutical company that develops and commercializes medicines for oncology, hematology, dermatology, and other therapeutic areas. The company focuses on bringing treatments to patients across multiple disease categories.
Immuneering4 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.
Companies competing with imCare Biotech for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $166.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $292.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does imCare Biotech do?
- ImCare Biotech develops diagnostic biomarkers and therapeutic drugs targeting liver diseases, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The company conducts research and development in molecular biology and tissue cultures.
- Who founded imCare Biotech?
- imCare Biotech was founded by Xuanyong Lu.
- How much funding has imCare Biotech raised?
- imCare Biotech has disclosed $4.3M raised across 5 rounds.
- Where is imCare Biotech headquartered?
- imCare Biotech is headquartered in Doylestown, US.